Introduction
Breastcancerisaglobalproblemandinmanycountriesthe most frequent malignancy in women. Although adjuvant treatmentwillbegiveninthemajorityofpatients,metastatic breastcancer(MBC)developsin30-40%ofallpatientswith breastcancer.Withdistantmetastasespresent,thediseaseis usuallynotcurableandremainsachallengeforthetreating physician.Mediansurvivalfromdiagnosisofmetastaticdisease is 2-3 years with only a minority of 5-10% of patients alivebeyond5years [1] .Theprimarygoalsoftreatmentare to control disease and symptoms, and to prolong life while minimizing toxicity. Further goals are to maintain physical andsocialfunctionaswellasqualityoflife(QoL).Endocrine therapyisthetreatmentoffirstchoiceinpatientswithpotential endocrine-sensitive tumors unless acute life-threatening or highly symptomatic disease has been diagnosed [2] . Furthermore,monotherapywithtrastuzumabmaybeareasonablealternativefirst-linetreatmenttoimmunochemotherapy in some patients with MBC and HER2 overexpression [3] . Unfortunately, the majority of these patients will have primaryresistanceoreventuallydevelopresistancetoendocrine treatment or immunotherapy. In this case, and in patients without sufficient hormone receptor or HER2 expression, chemotherapyisstillthemainstayoftreatmentinthemetastaticsetting.
Foralongtime,acommonassumptionhasbeenthatcombiningagentswillresultinbothsuperiorresponserates(RR) andincreaseddisease-freeorevenoverallsurvival.However, combinationchemotherapyhasalsobeenassociatedwithincreasedtreatmentcomplexityandtoxicityand,frequently,decreasedQoL.Thus,thequestionwhetherpolychemotherapy ispreferabletosequentialmonochemotherapyisstillunder debate [4] . This review will briefly summarize the results of trials comparing combination chemotherapy with monochemotherapy in patients with metastatic disease (table 1) and will demonstrate that in situations of MBC, combinationchemotherapyisareasonableapproachinthepalliative setting. Many of the trials included in these metaanalyses were of small size with poor methodology according to today's standards and, importantly, without prospectively plannedcrossoverinthesingleagentarm.However,inthose studies without planned crossover, the value of two agents versus a singleagentwas testedbut not thestrategy ofthe combination of two drugs versus the sequential use of the same two drugs. Furthermore, the majority of trials used nowadaysoutdatedchemotherapyregimensanddidnotassesstheimpactofthevariousregimensonQoL.Thus,itmay bemoreinformativetolookatthosesingletrialsinvestigatingagentsmorerecentlyintroducedintotheclinicandwith study designs comparing combination chemotherapy to the sequentialuseofthesamedrugs.Inthiscontext,itisimportanttonotethatthesequentialstrategyhasbeendefinedin two different ways. In some trials, the sequential approach was defined as the consecutive administration of several chemotherapiesfollowingdiseaseprogression,whichcanbe consideredastheclassicalsequentialapproach.Othertrials testedasequentialmonotherapyinanaprioriplannedmulticourse sequence of different chemotherapy agents as one line of treatment without disease progression and without treatmentinterruption.
Metaanalyses

Manytrialscomparingpolychemotherapywithmonochemo
Sequential Strategy Following Disease Progression
Themostinformativetrialcomparingcombinationtreatment with sequential treatment within this setting was reported by Sledge et al. [7] for the Eastern Cooperative Oncology Group (ECOG). In this trial, 739 patients with MBC without prior chemotherapy in the metastatic setting were randomized to either doxorubicin (A) or paclitaxel (P) alone, or to the combination of both drugs. At the time of progression, patients were crossed over from A to P and from P to A. Overall response and time to treatment failure were significantlyimprovedwiththecombinationtreatment,whereas overall survival was without significant differences between thethreetreatmentarms(A18.9months,P22.2months,AP 22.0 months). Furthermore, there were no significant differencesintheQoLscales(FACT-B)frombaselinetoweek16 between the treatment arms. A and P as single agents had equivalent activity, and the sequence of A and P was withBreastCare2009;4:367-372
RoleofCombinationChemotherapyinMBC 369 out importance as RR and time to progression (TTF) were similarforbothsequences(RR:P→A:20%,TTF4.2months; A→P: 22%, TTF 4.5 months). In a smaller trial conducted in Mexico [8] , 277 evaluable patients (of 368 enrolled) with anthracycline-pretreated MBC were randomized to capecitabine followed by a taxane (electively with either docetaxel orpaclitaxel)atthetimeofprogression,ortoacombination ofcapecitabineandataxane.64%ofthepatientstreatedup- front with capecitabine received docetaxel or paclitaxel as second-line treatment. In this study, RRs were numerically higherforthecombinationtreatmentbutwithoutstatistically significant improvement of TTP and overall survival after a median follow-up of 15.5 months. In a Finnish trial [9] , 303 patients with MBC without previous chemotherapy in the metastaticsetting,andwithonlyaminorityofpatientshaving hadadjuvantchemotherapy(20%),wererandomizedtoepirubicinefollowedbymitomycinCatthetimeofprogression (or when the maximum dose of epirubicin was reached), or combinationchemotherapywithcyclophosphamide,epirubicine, and 5-fluorouracil (CEF) followed by the combination ofmitomycinandvinblastinewhenprogressing(orwhenthe maximum cumulative dose of 1,000 mg/m 2 of epirubicin was reached).RRwasslightlyhigherwithCEFcomparedtoepirubicine(55vs.48%),butnosignificantdifferenceinTTP(12 vs.10.5months)andoverallsurvival(18vs.16months)was foundbetweenthetwogroups.Treatment-relatedtoxicitywas less in the single agent arms, and QoL analysis favored the patients treated with single agents. In a smaller randomized phase2trial [10] ,100patientsreceivedeitherthecombination ofdocetaxel(T:75mg/m 2 )andcapecitabine(X:1,250mg/m 2 twice daily (bid) d1-14), or the sequence of docetaxel (T: 100 mg/m 2 ) followed by capecitabine (X: 1,250 mg/m 2 bid,d1-14)inthecaseofprogression.Allpatientshadprior anthracyclines but no chemotherapy for MBC; only 20% of theenrolledpatientshadhormone-responsivedisease.74%of thepatientsinitiallytreatedwithdocetaxelreceivedcapecitabine upon progression reflecting clinical reality of daily routine. The post-study treatment was similar in both arms. In this trial, not only RR (68 vs. 40%, p = 0.004) and TTP (9.3vs.7.7months,p=0.001)butalsooverallsurvivalwere in favor of the combination treatment (22.0 vs. 19 months, p=0.006;HR0.528).However,toxicitywasincreasedinthe combination arm with more grade 3 and 4 diarrhea (12 vs. 8%),stomatitis(16vs.8%),andhand-footsyndrome(18vs. 4%).Neutropenicfeverwashighinbothtreatmentarmswith 12and14%.Dosereductionswerenecessaryfor52%ofpa-tientsonXTand36%ofpatientsonT→X.Therearesome caveatsregardingtheresultsofthistrial.Thenumbersinthis trialarelow,theRRofalmost70%ismuchhigherthanRRs usuallyreportedinphase3trials,andthistrialhasnotbeen fullypublishedinapeerreviewjournaleventhoughthefirst results were reported more than 3 years ago. Thus, to draw definitive conclusions from this trial for clinical practice, these results need to be confirmed in a bigger cohort of patients.Andevenifthedataareconfirmed,thesmallsurvival benefithastobeweighedagainsttheexcessivetoxicityinpatients where a cure is usually not achieved. In another trial [11] ,752anthracycline-pretreatedandtaxane-resistantMBC patientswererandomizedtothecombinationofixabepilone and capecitabine or to capecitabine alone. Patients were allowed to have 3 prior chemotherapy regimens, and about half the patients did in fact have 2 or 3 prior chemotherapy regimens for metastatic disease. In these heavily pretreated patients, ixabepilone plus capecitabine prolonged TTP (median5.8vs.4.2months)relativetocapecitabine.RRwasalso significantly increased with the combination treatment (35 vs. 14%). Grade 3/4 treatment-related sensory neuropathy (21vs.0%),fatigue(9vs.3%),andneutropenia(68vs.11%) were more frequent with the combination therapy. Overall survivalwasnotsignificantlydifferentbetweenthetreatment groups(12.9vs.11.1months,p=0.1936).Nodatahavebeen reported regarding crossover and post-study treatment. Impact of treatment on symptoms measured by FACT-Breast Symptom Index 8 revealed a statistically significant difference in favor of capecitabine. This combination may be an optioninsomeanthracycline-andtaxane-pretreatedpatients where the achievement of a quick remission is of utmost importance.
Sequential Strategy without Disease Progression or Interruption
Inarandomizedphase3trial [12] ,MBCpatientspretreated with anthracyclines in the (neo)adjuvant or metastatic settingwererandomizedtoeitherthecombinationofdocetaxel andgemcitabinefor8cycles,orto4cyclesofdocetaxelfol-lowedby4cyclesofgemcitabine.Samplesizewascalculated to be 430; however, due to poor recruitment, the trial was closedprematurelyafterenrollmentof100patientsonly.No difference in RR, TTP, or overall survival was seen. Hematologic toxicity was higher in the sequential arm. In another trialreportedbyConteetal. [13] ,4cyclesofepirubicinefol-lowed by 4 cycles of paclitaxel was compared to 8 cycles of the combination of these two drugs in 202 patients not previously treated with chemotherapy in the metastatic setting. RR, median progression-free survival, and overall survival werenotsignificantlydifferentbetweenthetreatmentarms. Grade3/4neutropeniaandgrade2neurotoxicitywashigher inthesequentialarm.InatrialconductedinSpainbyGEI-CAM [14] ,144patientswithoutpriorchemotherapyforMBC wererandomizedto3cyclesofdoxorubicinfollowedby3cy-cles of docetaxel, or to the combination of doxorubicin and docetaxel. RR, TTP, and survival were similar between the treatmentarms;however,toxicityintermsoffebrileneutropenia, asthenia, and diarrhea was higher in the combination regimen.InatrialbyaGreekstudygroup [15] ,183patients with MBC without chemotherapy in the advanced setting wereenrolled.Patientswererandomlyassignedtoacombinationofepirubicineandpaclitaxelfor6cyclesatconventional dosesandintervals,ortothesequenceofdose-intensifiedand dose-denseepirubicinefor3cyclesfollowedimmediatelyby 3cyclesofpaclitaxel(againdose-intensifiedanddose-dense) with growth factor support. No difference in RR, TTP, and overallsurvivalwasseen.
Single Trials with Overall Survival Benefit
In a phase 3 multicenter trial [16] , a total of 529 patients with MBC were randomly assigned to the combination of gemcitabine and paclitaxel (GP) or to paclitaxel (P) alone. Priorchemotherapyinthemetastaticsettingwasnotallowed; the majority of patients had prior anthracycline-containing (neo)adjuvanttherapy(96% were slightly increased with the combination. Treatmentrelated discontinuation was low in both groups (GP 6.1%, P 3.5%). Further therapy following progression was not pre-specified, and 55% of patients received additional chemotherapy after completion of the study treatment (except for gemcitabine, the types of additional chemotherapy were very similar in the two arms). A crossover after paclitaxel monotherapy to gemcitabine was not mandatory, and only 15.6% of the patients starting with paclitaxel actually received gemcitabine. QoL was reported to be better inpatientswiththecombinationtreatment.Inanothertrial [17] , 511 patients with MBC and anthracycline pretreatmentwererandomizedtodocetaxel(T100mg/m 2 )aloneor to docetaxel (75 mg/m 2 ) in combination with capecitabine (X 1,250 mg/m 2 bid). Similar to the previously mentioned trial [16] , RR (42 vs. 30%), TTP (6.1 vs. 4.2 months), and overall survival (14.5 vs. 11.5 months) favored the combination approach. However, grade 3 and 4 toxicities were more frequently observed with the combination treatment, particularly more diarrhea, stomatitis, and hand-foot syndrome.Dosereduction(in51%ofbothdrugs)wasrequired in 65% of the patients. Treatment-related discontinuation was higher in patients treated with the combination of both drugs (26 vs. 20%). The majority of patients received post-study chemotherapy (70% after TX, 63% after T), andonly17%ofthepatientsinthesingleagentgroupcrossed over to capecitabine. QoL for global health was assessed in 454 patients and was similar between the two treatment arms.
Conclusion
Data are quite consistent with significantly increased RRs andTTPwithcombinationchemotherapycomparedtosingle agentsinpatientswithMBC.Toxicitywashigherwithpolychemotherapy although QoL was not always adversely influencedbyincreasedtoxicity.Regardinganoverallsurvival benefit with the use of combination chemotherapy, the data arenotasrobustaswithTTPandRR.Asurvivalbenefitis notdefinitivelyproven,sinceinthosetrialsshowinganoverall survivalbenefitforthecombinationapproach,onlyaminorityofthecaseshadacrossovertotheotheragentinthemonotherapyarm.Inpatientswithsymptomaticdiseaseoracute life-threatening disease, where maximum response is important, polychemotherapy is preferred to monotherapy. Since some combination regimens seem to increase toxicity only slightly(e.g.paclitaxel,gemcitabine)andsignificantlyprolong TTP,polychemotherapymaybeanoptionforpatientsother thantheabove,characterizedashigh-riskpatients.However, whentransferringthesetrialdataintoroutinepractice,cliniciansshouldbeawarethatthestrictinclusionandexclusion criteriaofclinicaltrialsfrequentlyresultinaselectedpatient population,whichmaylimittheextrapolationofstudyresults andthustheapplicabilityofstudy-testedregimenstothegeneralpopulation.Thus,treatmentdecisionsshouldbebasedon theindividualpatient'sneedsandpreferencesandincludeher medical history, comorbidities, and social situation. Newer combination therapy may also involve the combination of a cytotoxic drug with a novel biologic agent (e.g. trastuzumab orbevacizumab) [18, 19] .Ithasbeenshownthatthese'new' combinations are more effective in terms of RR, TTP, and, for trastuzumab, also overall survival. Comparisons of these newer combinations (e.g. chemotherapy + bevacizumab) to traditionalcombinationchemotherapyareeagerlyawaited.
